TY - JOUR
T1 - Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma
AU - Matsuo, Koji
AU - Takazawa, Yutaka
AU - Ross, Malcolm S.
AU - Elishaev, Esther
AU - Yunokawa, Mayu
AU - Sheridan, Todd B.
AU - Bush, Stephen H.
AU - Klobocista, Merieme M.
AU - Blake, Erin A.
AU - Takano, Tadao
AU - Baba, Tsukasa
AU - Satoh, Shinya
AU - Shida, Masako
AU - Ikeda, Yuji
AU - Adachi, Sosuke
AU - Yokoyama, Takuhei
AU - Takekuma, Munetaka
AU - Yanai, Shiori
AU - Takeuchi, Satoshi
AU - Nishimura, Masato
AU - Iwasaki, Keita
AU - Johnson, Marian S.
AU - Yoshida, Masayuki
AU - Hakam, Ardeshir
AU - Machida, Hiroko
AU - Mhawech-Fauceglia, Paulette
AU - Ueda, Yutaka
AU - Yoshino, Kiyoshi
AU - Kajiwara, Hiroshi
AU - Hasegawa, Kosei
AU - Yasuda, Masanori
AU - Miyake, Takahito M.
AU - Moriya, Takuya
AU - Yuba, Yoshiaki
AU - Morgan, Terry
AU - Fukagawa, Tomoyuki
AU - Pejovic, Tanja
AU - Nagano, Tadayoshi
AU - Sasaki, Takeshi
AU - Richmond, Abby M.
AU - Post, Miriam D.
AU - Shahzad, Mian M.K.
AU - Im, Dwight D.
AU - Yoshida, Hiroshi
AU - Enomoto, Takayuki
AU - Omatsu, Kohei
AU - Ueland, Frederick R.
AU - Kelley, Joseph L.
AU - Karabakhtsian, Rouzan G.
AU - Roman, Lynda D.
N1 - Publisher Copyright:
© 2018, Society of Surgical Oncology.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Purpose: To propose a categorization model of uterine carcinosarcoma (UCS) based on tumor cell types (carcinoma and sarcoma) and sarcoma dominance. Methods: This secondary analysis of a prior multicenter retrospective study examined 889 cases of UCS with available histologic evaluation. Based on survival outcome, cases were clustered into three groups: low-grade carcinoma with nondominant homologous sarcoma [type A, n = 96 (10.8%)], (1) low-grade carcinoma with heterologous sarcoma or any sarcoma dominance and (2) high-grade carcinoma with nondominant homologous sarcoma [type B, n = 412 (46.3%)], and high-grade carcinoma with heterologous sarcoma or any sarcoma dominance [type C, n = 381 (42.9%)]. Tumor characteristics and outcome were examined based on the categorization. Results: Women in type C category were more likely to be older, obese, and Caucasian, whereas those in type A category were younger, less obese, Asian, and nulligravid (all P < 0.01). Type C tumors were more likely to have metastatic implants, large tumor size, lymphovascular space invasion with sarcoma cells, and higher lymph node ratio, whereas type A tumors were more likely to be early-stage disease and small (all P < 0.05). On multivariate analysis, tumor categorization was independently associated with progression-free survival (5-year rates: 70.1% for type A, 48.3% for type B, and 35.9% for type C, adjusted P < 0.01) and cause-specific survival (5-year rates: 82.8% for type A, 63.0% for type B, and 47.1% for type C, adjusted P < 0.01). Conclusion: Characteristic differences in clinicopathological factors and outcomes in UCS imply that different underlying etiologies and biological behaviors may be present, supporting a new classification system.
AB - Purpose: To propose a categorization model of uterine carcinosarcoma (UCS) based on tumor cell types (carcinoma and sarcoma) and sarcoma dominance. Methods: This secondary analysis of a prior multicenter retrospective study examined 889 cases of UCS with available histologic evaluation. Based on survival outcome, cases were clustered into three groups: low-grade carcinoma with nondominant homologous sarcoma [type A, n = 96 (10.8%)], (1) low-grade carcinoma with heterologous sarcoma or any sarcoma dominance and (2) high-grade carcinoma with nondominant homologous sarcoma [type B, n = 412 (46.3%)], and high-grade carcinoma with heterologous sarcoma or any sarcoma dominance [type C, n = 381 (42.9%)]. Tumor characteristics and outcome were examined based on the categorization. Results: Women in type C category were more likely to be older, obese, and Caucasian, whereas those in type A category were younger, less obese, Asian, and nulligravid (all P < 0.01). Type C tumors were more likely to have metastatic implants, large tumor size, lymphovascular space invasion with sarcoma cells, and higher lymph node ratio, whereas type A tumors were more likely to be early-stage disease and small (all P < 0.05). On multivariate analysis, tumor categorization was independently associated with progression-free survival (5-year rates: 70.1% for type A, 48.3% for type B, and 35.9% for type C, adjusted P < 0.01) and cause-specific survival (5-year rates: 82.8% for type A, 63.0% for type B, and 47.1% for type C, adjusted P < 0.01). Conclusion: Characteristic differences in clinicopathological factors and outcomes in UCS imply that different underlying etiologies and biological behaviors may be present, supporting a new classification system.
UR - http://www.scopus.com/inward/record.url?scp=85051853042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051853042&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6695-z
DO - 10.1245/s10434-018-6695-z
M3 - Article
C2 - 30105438
AN - SCOPUS:85051853042
SN - 1068-9265
VL - 25
SP - 3676
EP - 3684
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 12
ER -